Effects of Rituximab Including Long-term Maintenance Therapy in Children with Nephrotic Syndrome in a Single Center of Korea
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Rituximab (RTX) is a chimeric monoclonal antibody that inhibits CD20-mediated B-cell proliferation and differentiation. Several studies have examined its use in intractable nephrotic syndrome (NS) with some positive results. However, those studies examined such effects for a short-term period of 1 year, and some patients continued to relapse after a lapse in RTX treatment. Our use of RTX as a maintenance therapy (RTX injection when the CD19 cell count exceeded 100–200/μL before relapse) showed some noticeable efficacy. We used RTX in 19 patients with steroid-dependent NS (SDNS). In 12 patients treated with RTX maintenance therapy, only one relapse occurred. The mean treatment period was 23.4±12.7 months, and the mean number of RTX administrations was 3.9±1.6. The relapse rates were decreased (from 2.68/year to 0.04/year), and the drug-free period also increased (from 22.5 days/year to 357.1 days/year) during maintenance therapy. The other seven patients were treated with one cycle of RTX or additional cycles in case of relapse (non-maintenance therapy). Relapse rates were significantly decreased after RTX treatment (from 1.76/year to 0.96/year, P =0.017). The relapsefree period was 15.55±7.38 (range, 5.3–30.7) months. No severe side effects of RTX were found except for a hypersensitivity reaction such as fever and chills during its infusion. In conclusion, RTX is considered an effective and safe option to reduce the relapse rate by a single- or maintenance-interval therapy in SDNS.
Abstract
Rituximab (RTX) is a chimeric monoclonal antibody that inhibits CD20-mediated B-cell proliferation and differentiation. Several studies have examined its use in intractable nephrotic syndrome (NS) with some positive results. However, those studies examined such effects for a short-term period of 1 year, and some patients continued to relapse after a lapse in RTX treatment. Our use of RTX as a maintenance therapy (RTX injection when the CD19 cell count exceeded 100–200/μL before relapse) showed some noticeable efficacy. We used RTX in 19 patients with steroid-dependent NS (SDNS). In 12 patients treated with RTX maintenance therapy, only one relapse occurred. The mean treatment period was 23.4±12.7 months, and the mean number of RTX administrations was 3.9±1.6. The relapse rates were decreased (from 2.68/year to 0.04/year), and the drug-free period also increased (from 22.5 days/year to 357.1 days/year) during maintenance therapy. The other seven patients were treated with one cycle of RTX or additional cycles in case of relapse (non-maintenance therapy). Relapse rates were significantly decreased after RTX treatment (from 1.76/year to 0.96/year, P =0.017). The relapsefree period was 15.55±7.38 (range, 5.3–30.7) months. No severe side effects of RTX were found except for a hypersensitivity reaction such as fever and chills during its infusion. In conclusion, RTX is considered an effective and safe option to reduce the relapse rate by a single- or maintenance-interval therapy in SDNS.
참고문헌 (25)
- Ehrich JHH, "Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated", Nephrol Dial Transplant, 22, pp.2183~2193 (2007)[DOI]
- Kyrieleis HAC, "Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children", Clin J Am Soc Nephrol CJASN, 4, pp.1593~1600 (2009)[DOI]
- Guigonis V, "RTX treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases", Pediatr Nephrol, 23, pp.1269~1279 (2008)[DOI]
- Bagga A, "RTX in patients with the steroidresistant nephrotic syndrome", N Engl J Med, 356, pp.2751~2752 (2007)[DOI]
- Gilbert RD, "RTX therapy for steroid-dependent minimal change nephrotic syndrome", Pediatr Nephrol, 21, pp.1698~1700 (2006)[DOI]
- Keystone E, "Safety and efficacy of additional courses of RTX in patients with active rheumatoid arthritis: an open-label extension analysis", Arthritis Rheum, 56, pp.3896~3908 (2007)[DOI]
- Looney RJ, "B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I", II dose-escalation trial of RTX, 2004, pp.50, 2580~2589
- Benz K, "Change of the course of steroid-dependent nephrotic syndrome after RTX therapy", Pediatr Nephrol, 19, pp.794~797 (2004)[DOI]
- Sinha A, "Efficacy and safety of RTX in children with difficult-to-treat nephrotic syndrome", Nephrol Dial Transplant, 30, pp.96~106 (2015)[DOI]
- Kemper MJ, "Long-term follow-up after RTX for steroid-dependent idiopathic nephrotic syndrome", Nephrol Dial Transplant, 27, pp.1910~1915 (2012)[DOI]
- Iijima K, "RTX for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial", Lancet, 384, pp.1273~1281 (2014)[DOI]
- Gulati A, "Efficacy and safety of treatment with RTX for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report", Clin J Am Soc Nephrol, 5, pp.2207~2212 (2010)[DOI]
- Kaito H, "Successful treatment of collapsing focal segmental glomerulosclerosis with a combination of RTX, steroids and ciclosporin", Pediatr Nephrol, 25, pp.957~959 (2010)[DOI]
- Magnasco A, "RTX in children with resistant idiopathic nephrotic syndrome", J Am Soc Nephrol, 23, pp.1117~1124 (2012)[DOI]
- Cravedi P, "Titrating RTX to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy", Clin J Am Soc Nephrol, 2, pp.932~937 (2007)[DOI]
- Kamei K, "Single dose of RTX for refractory steroid-dependent nephrotic syndrome in children", Pediatr Nephrol, 24, pp.1321~1328 (2009)[DOI]
- Fujinaga S, "Single infusion of RTX for persistent steroid-dependent minimalchange nephrotic syndrome after long-term cyclosporine", Pediatr Nephrol, 25, pp.539~544 (2010)[DOI]
- Ito S, "Survey of RTX treatment for childhood-onset refractory nephrotic syndrome", Pediatr Nephrol, 28, pp.257~264 (2013)[DOI]
- Niu X-L, "Single dose of RTX in children with steroid-dependent minimal change nephrotic syndrome", Biomed Rep, 5, pp.237~242 (2016)[DOI]
- Tellier S, "Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome", Pediatr Nephrol, 28, pp.911~918 (2013)[DOI]
- Cornec D, "Identification of patients with indolent B cell lymphoma sensitive to RTX monotherapy", Ann Hematol, 91, pp.715~721 (2012)[DOI]
- Igarashi T, "Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with RTX: a Japanese phase II study", Ann Oncol, 13, pp.928~943 (2002)[DOI]
- Ahn YH, "Development of antiRTX antibodies in children with nephrotic syndrome", Pediatr Nephrol, 29, pp.1461~1464 (2014)[DOI]
- Chaumais M-C, "Fatal pulmonary fibrosis after RTX administration", Pediatr Nephrol, 24, pp.1753~1755 (2009)[DOI]
- Sellier-Leclerc A-L, "Fulminant viral myocarditis after RTX therapy in pediatric nephrotic syndrome", Pediatr Nephrol, 28, pp.1875~1879 (2013)[DOI]